Golodirsen, Potential Exon 53 Skipping Therapy for Duchenne, Under Priority Review by FDA
News
Sarepta Therapeutics announced that the U.S Food and Drug Administration (FDA) has accepted its application for a priority review of golodirsen (SRP-4053), a potential treatment for Duchenne muscular dystrophy (DMD) patients amenable ... Read more